Longevity Papers Podcast

In this episode of Longevity Papers, we analyze five standout papers from longevitypapers.com covering the past four weeks of longevity research (February-March 2026): 1) Microbiome depletion rejuvenates the aging brain (Gasperini, Holton, Limone et al., Harvard University, February 15, 2026, bioRxiv, https://www.biorxiv.org/content/10.64898/2026.02.13.705770v1 ) - Antibiotic-induced microbiome depletion in aged mice triggers widespread brain rejuvenation including improved neurogenesis, myelination, vascular density, and memory. The aged gut microbiome drives brain aging through eotaxin-1 (CCL11) - the same factor found elevated in old blood in the classic heterochronic parabiosis studies. Inhibiting eotaxin-1 alone was sufficient to reverse multiple brain aging hallmarks. 2) Transplanting ANXA1- CD8+ Naive T cells Delay Aging Through Senolysis (Wu, Guo, Zhang et al., Shanghai Jiao Tong University, February 23, 2026, bioRxiv, https://www.biorxiv.org/content/10.64898/2026.02.21.707223v1 ) - Monthly transfer of ANXA1-deficient CD8+ naive T cells into aged mice extended median lifespan by more than 30 weeks and improved cardiac function, bone density, and motor coordination. The aging immune system fails to clear senescent cells because CD8+ naive T cells accumulate an ANXA1+ senescent-like subpopulation. Removing this subpopulation restores immune senolysis. 3) Organism-wide cellular dynamics and epigenomic remodeling in mammalian aging (Lu, Zhang, Xu et al., Rockefeller University, February 26, 2026, Science, https://www.science.org/doi/10.1126/science.adw6273 ) - Landmark single-cell chromatin atlas of approximately 7 million cells across 21 mouse tissues at three ages reveals that 25% of cell types show dramatic age-related population shifts including loss of kidney podocytes, muscle tenocytes, and lung aerocytes. Critically, 40% of aging dynamics differ between males and females. 4) The glycolytic metabolite phosphoenolpyruvate restricts cGAS-driven inflammation to promote healthy aging (Song, Hu, Zhang et al., Nanhu Laboratory, March 7, 2026, Nature Aging, https://www.nature.com/articles/s43587-026-01087-1 ) - PEP, a normal glycolytic intermediate, is an endogenous cGAS inhibitor that declines with age, unleashing cGAS-STING-driven inflammaging. Restoring PEP before its natural age-related decline promotes healthy aging in mice and alleviates Alzheimer's disease symptoms. 5) Cellular Aging Signatures in the Plasma Proteome Record Human Health and Disease (Ding, Bot, Chen et al., Stanford University, February 12, 2026, bioRxiv, https://www.biorxiv.org/content/10.64898/2026.02.10.704909v1 ) - The largest plasma proteomics aging study ever: 60,000 individuals, 7,000+ proteins, biological age estimates for 40+ cell types. APOE4 carriers show older astrocytes but younger macrophages, directly linking cell-type-specific aging to Alzheimer's disease risk. Cellular aging signatures predict incident disease and mortality over 15 years of follow-up. This podcast is AI generated and may contain errors.

In this episode, we discuss five groundbreaking papers from longevitypapers.com on mechanisms of aging and potential interventions: 1) Enhanced non-enzymatic H2S generation via natural diallyl sulforated compounds extends lifespan and healthspan in mice (Cáliz-Molina et al., Cell Metabolism, December 2025, https://pubmed.ncbi.nlm.nih.gov/41421349/ ) - Diallyl sulforated compounds boost endogenous hydrogen sulfide, improving mitochondrial function, suppressing mTOR-related aging pathways, and restoring protein persulfidation in aged mice. This non-pharmacological approach addresses multiple hallmarks of aging. 2) Selective activation of NaV1.3 restores lymphatic contractility in aging and injury (Ruscic et al., Massachusetts General Hospital, December 2025, https://www.biorxiv.org/content/10.64898/2025.12.15.694318v1 ) - A newly identified voltage-gated sodium channel selectively expressed in lymphatic muscle can be pharmacologically activated to restore lymphatic pumping in aged mice, addressing a previously untargeted aging system critical for immunity and metabolic homeostasis. 3) Mitochondrial RNA cytosolic leakage drives the SASP (Victorelli et al., Mayo Clinic, December 2025, https://pubmed.ncbi.nlm.nih.gov/41392167/ ) - Beyond mtDNA, mitochondrial RNA leakage activates RIG-I and MDA5 sensors to drive senescence-associated inflammation. BAX/BAK deletion reduces SASP, suggesting RNA sensors as novel druggable targets. 4) Awakening intracellular immunity for functional HIV cure via CD4 T cell reprogramming (Lanna et al., University College London, January 2026, https://www.biorxiv.org/content/10.64898/2026.01.08.698387v1 ) - Transient CD4 T cell reprogramming activates antiviral telomere transfer programs that eliminate integrated HIV DNA, offering potential functional cure. Since HIV accelerates epigenetic aging by ~13 years, this is transformative for aging in HIV+ populations and may generalize to other age-related immune dysfunction. 5) Rapamycin exerts geroprotective effects by enhancing DNA damage resilience in human immune cells (Kell et al., University of Oxford, January 2026, https://pubmed.ncbi.nlm.nih.gov/41546123/ ) - First human mechanistic study of low-dose rapamycin shows direct genoprotection of aged T cells through reduced DNA lesional burden and p21 suppression. Off-patent, low-cost, and immediately clinically translatable. This podcast is AI generated and may contain errors.

A Fourfold Male-Specific Lifespan Extension via Canonical Insulin/IGF-1 Signaling (Russell et al., University of Alabama at Birmingham, December 5, 2025, BioRxiv, https://www.biorxiv.org/content/10.64898/2025.12.02.691904v1 ) - We explore how the daf-2 mutation extends male C. elegans lifespan by an extraordinary 4-fold with preserved healthspan, establishing sex as a primary determinant of longevity potential rather than a secondary variable. This challenges our understanding of insulin/IGF-1 signaling and suggests sex-specific interventions may be critical for anti-aging therapeutics. 2) Lifespan-extending downregulation of insulin signaling reduces germline mutation load (Duxbury et al., University of East Anglia, December 5, 2025, BioRxiv, https://www.biorxiv.org/content/10.64898/2025.12.05.692572v1 ) - We examine how reducing insulin/IGF-1 signaling in adulthood simultaneously extends somatic lifespan and reduces germline mutation rates by ~50 percent, dissolving the classical reproductive-somatic trade-off. The HRDE-1 epigenetic silencing pathway emerges as a novel mechanism linking nutrient sensing to genome stability across generations. 3) A Global Metabolomic and Lipidomic Landscape of Human Plasma Across the Lifespan (Liu et al., University of Science and Technology of China, December 6, 2025, Aging Cell, https://pubmed.ncbi.nlm.nih.gov/41351469/ ) - We discuss how untargeted metabolomics of 136 individuals reveals nonlinear metabolic trajectories with critical transition points, elevated amino acids and lipid dysbalance characterizing aging, and development of a clinically applicable plasma metabolite-based aging clock that may outperform epigenetic clocks for mortality prediction. 4) Genome-wide association study of proteomic aging reveals shared genetic architectures with longevity, early life development, and age-related diseases (Argentieri et al., Massachusetts General Hospital, December 4, 2025, MedRxiv, https://www.medrxiv.org/content/10.64898/2025.12.03.25341518v1 ) - We analyze 27 genetic loci associated with proteomic age gap showing strong genetic correlation with longevity (r=-0.83), with validated polygenic scores predicting increased odds of exceptional longevity and mechanistic links to FTO and m6A methylation-regulated metabolic aging. 5) Gut metabolism links precision nutrition, exercise, and healthspan in Drosophila melanogaster

In this episode, we analyze four standout papers from longevity research (November 17–30, 2025). The sources indicate that none achieve the paradigm-shifting breakthrough required for decades-long (10+ year) human lifespan extension. 1. Targeting Nuclear Tension to Rejuvenate Blood (Paper #74) Title: Targeting RhoA nuclear mechanoactivity rejuvenates aged hematopoietic stem cells Authors: Eva Mejía-Ramírez, Pablo Iáñez Picazo, Barbara Walter, et al. Source/Date: Nature Aging, November 25, 2025 URL: https://pubmed.ncbi.nlm.nih.gov/41286... This paper identifies a genuinely novel mechanotransduction axis (NE tension → P-cPLA2 → RhoA) in aging hematopoietic stem cells (HSCs). Aged HSCs accumulate pathological nuclear envelope (NE) tension, which hyperactivates RhoA signaling, leading to loss of youthful H3K9me2 heterochromatin and de-repression of retrotransposons. RhoA inhibition pharmacologically restores NE homeostasis, recovers H3K9me2, and improves HSC regenerative capacity and lymphomyeloid balance in vivo. This work is strong mechanistic discovery, but the effects are HSC-specific. Systemic longevity impact is limited, potentially leading to 2–4 year healthspan gains in immune resilience in highly optimized scenarios, falling short of transformative longevity goals. 2. AI Agents for Intervention Discovery (Paper #41) Title: Autonomous AI Agents Discover Aging Interventions from Millions of Molecular Profiles Authors: Ying, K., Tyshkovskiy, A., Moldakozhayev, A., et al. Source/Date: BioRxiv, November 20, 2025 URL: https://www.biorxiv.org/content/10.11... This research uses the ClockBase Agent to autonomously reanalyze 43,602 intervention-control comparisons across multiple aging clocks. It identified over 500 interventions that reduce biological age, including ouabain. Experimental validation showed ouabain reduced frailty, decreased neuroinflammation, and improved cardiac function in aged mice. This represents genuine methodological novelty in mining existing biomedical data for aging interventions, but the intervention (ouabain) is a known cardiac glycoside, and the effects are considered modest. 3. Splicing Dysregulation in Muscle Aging (Paper #22) Title: TGFβ-Smad3 signaling restores cell-autonomous Srsf1-mediated splicing of fibronectin in aged skeletal muscle stem cells Authors: Yuguo Liu, Svenja C Schüler, Simon Dumontier, et al. Source/Date: Nature Communications, November 22, 2025 URL: https://pubmed.ncbi.nlm.nih.gov/41271... This paper maps the TGFβ1-Smad3-Srsf1-EDB(+)FN pathway linking RNA splicing dysregulation to muscle regenerative failure in aging. TGFβ1 activation restored fibronectin splicing and improved muscle repair in aged mice during a defined regeneration interval. This is solid mechanistic work aligning with RNA splicing being an emerging core aging axis. However, the therapeutic window appears narrow, confined to acute regeneration intervals, and lacks whole-organism lifespan data. 4. The Nonhuman Primate Aging Atlas (Paper #70) Title: A multi-omics molecular landscape of 30 tissues in aging female rhesus macaques Authors: Gong-Hua Li, Xiang-Qing Zhu, Fu-Hui Xiao, et al. Source/Date: Nature Methods, November 18, 2025 URL: https://pubmed.ncbi.nlm.nih.gov/41249... This is the first comprehensive multi-omics atlas across 30 tissues in nonhuman primates. The key finding is that tissue aging is asynchronous and stratified by mRNA translation efficiency; tissues with declining translational capacity exhibit accelerated aging and drive whole-body aging. This paper links translational capacity to tissue-specific aging rates but is primarily descriptive, providing an excellent resource rather than interventional proof of lifespan extension. Overall Assessment: This body of work is valuable for resource building and hypothesis generation, focusing on incremental improvements across areas like mechanotransduction, translational capacity, and AI methodology. However, none provide the clear therapeutic path or fundamental aging reversal mechanism necessary to achieve breakthroughs targeting decades-long human lifespan extension. This podcast is AI generated and may contain errors.

In this episode of Longevity Papers, we critically analyze the five most impactful papers from this week (November 10-14, 2025) selected from longevitypapers.com for biotech researchers and longevity enthusiasts. 1) 'circHERC1-A telomerase activator' (Yumeng Cui et al., Beijing Institute of Biotechnology, November 12, 2025, Science Advances, https://pubmed.ncbi.nlm.nih.gov/41223261/ ) - We explore how the circular RNA circHERC1 activates telomerase expression by recruiting RNA Pol II to the TERT promoter. Notably, circHERC1 declines with age, correlating with reduced telomerase activity. Restoration via AAV or extracellular vesicles enhances telomere elongation and reverses aging phenotypes including improved cognition and physical performance. This addresses telomere attrition as a hallmark of aging, building on decades of telomerase biology since Greider/Blackburn 1985, with a unique endogenous regulatory mechanism distinct from previous failed small-molecule approaches. 2) 'HDAC2 inhibition restores H4K16 Acetylation and Rescues Cellular Senescence in Hutchinson-Gilford progeria syndrome' (Karimpour et al., University of Alberta, November 7, 2025, BioRxiv, https://www.biorxiv.org/content/10.1101/2025.11.07.687234v1 ) - We examine how systematic screening identified HDAC2 (not SIRT1) as the dominant deacetylase responsible for H4K16ac loss in accelerated aging. Pharmacological HDAC2 inhibition restores H4K16 acetylation, rescuing nuclear morphology, proliferative capacity, and reducing senescence in HGPS cells. This represents a specificity win over pan-HDAC inhibitors that failed clinically, with potential transformative implications if HGPS lifespan is extended, proving concept for broader aging populations. 3) 'Targeting Endothelial KDM5A to Attenuate Aging and Ameliorate Age-Associated Metabolic Abnormalities' (Rifeng Gao et al., Zhejiang University, November 14, 2025, Advanced Science, https://pubmed.ncbi.nlm.nih.gov/41236095/ ) - We discuss how endothelial-specific KDM5A deficiency causes shortened lifespan with senescent phenotypes (fat accumulation, reduced thermogenesis, kyphosis), demonstrating causative endothelial aging. The mechanism links epigenetics to metabolism: KDM5A regulates H3K4me3 at FABP4 promoters. Maintaining VEC-specific KDM5A prolongs lifespan, establishing the KDM5A/FABP4 axis as a therapeutic target for vascular aging and systemic metabolic dysfunction. 4) 'Mitochondrial dysfunction drives age-related degeneration of the thoracic aorta' (Arjune S Dhanekula et al., University of Washington, November 14, 2025, GeroScience, https://pubmed.ncbi.nlm.nih.gov/41233677/ ) - We analyze how elamipretide (SS-31), a mitochondria-targeted peptide in clinical trials, restores Complex II respiration to young levels in aged aortas, reducing stiffness, elastin breaks, and inflammatory MMP9 expression. This demonstrates causation via pharmacological rescue of a hallmark aging process, with SS-31 already being tested in Friedreich's ataxia and heart failure—this aging application would expand clinical relevance significantly. 5) 'Defining Microbiota-Derived Metabolite Butyrate as a Senomorphic: Therapeutic Potential in the Age-Related T Cell Senescence' (Nia Paddison Rees et al., University of Birmingham, November 7, 2025, Aging Cell, https://pubmed.ncbi.nlm.nih.gov/41201238/ ) - We examine butyrate as a senomorphic agent preventing senescence accumulation rather than eliminating it. The mechanism: butyrate suppresses IL-6/IL-8 SASP secretion via mTOR/NF-κB inhibition, with reduced DNA damage markers and mitochondrial ROS. Young fecal microbiota reverse aged splenic senescence in vivo, implicating the microbiota-immune axis. Butyrate is dietary, cheap (0/month), and represents a scalable intervention if lifespan studies confirm efficacy. This podcast is AI generated and may contain errors.

In this episode of Longevity Papers podcast, we discuss three cutting-edge papers on aging mechanisms and potential interventions, featured this week on longevitypapers.com. 1) Decay in transcriptional information flow is a hallmark of cellular aging (Emison et al., Yale University, October 30, 2025, biorxiv, https://www.biorxiv.org/content/10.1101/2025.10.30.685689v1 ) - We explore a novel information-theoretic framework showing that aging is fundamentally a loss of coordinated transcription factor activity across networks. The authors use single-cell RNA-seq across ten tissues to show mutual information between transcription factors and target genes declines with age, but crucially, in silico upregulation of key transcription factors restores youthful gene expression patterns. This offers a systems-level understanding of aging and suggests targeted transcription factor reinforcement as a rejuvenation strategy. 2) FOXM1 enhances DNA repair in aged cells to maintain the peripheral heterochromatin barrier to senescence enhancers (Sousa-Soares et al., Universidade do Porto, October 30, 2025, biorxiv, https://www.biorxiv.org/content/10.1101/2025.10.29.685369v1 ) - We examine a powerful age-reversal mechanism where FOXM1 induction restores epigenetic integrity in aged cells. The pathway is elegant: FOXM1 drives DNA repair genes, preserves the G9a methyltransferase, maintains H3K9me2 heterochromatin at the nuclear periphery, and thereby silences senescence-enhancer landscapes. This work identifies FOXM1 as a potential age-reversal factor rather than merely slowing decline. 3) Lactobacillus Salivarius-Derived Indole-3-Acetic Acid Promotes AHR-PARP1 Axis-Mediated DNA Repair to Mitigate Intestinal Aging (Cao et al., Chinese Academy of Sciences, October 28, 2025, Advanced Science, https://pubmed.ncbi.nlm.nih.gov/41147383/ ) - We discuss a concrete, translatable microbiota-to-DNA repair axis where bacterial indole-3-acetic acid activates the aryl hydrocarbon receptor, which potentiates PARP1 activity to enhance DNA repair in intestinal epithelial cells. This identifies Lactobacillus salivarius as a candidate probiotic intervention and offers a direct path to clinical trials. Together, these papers represent some of the strongest mechanistic work on aging this week, combining systems biology, epigenetics, and microbiome approaches. This podcast is AI generated and may contain errors.

In this episode of Longevity Papers, we critically analyze five research papers from the week of October 13-19, 2025, curated from longevitypapers.com: 1) Mutation-Agnostic Base Editing of the Progerin Farnesylation Site Rescues Hutchinson-Gilford Progeria Syndrome Phenotypes in Neuromuscular Organoids (Kim et al., Seoul National University, October 16, 2025, bioRxiv, https://www.biorxiv.org/content/10.1101/2025.10.16.682736v1 ) - We examine the FATE platform for treating progeria through mutation-agnostic base editing, discussing its potential and significant translation challenges including organoid model limitations and in vivo delivery obstacles. 2) Phenome-Wide Multi-Omics Integration Uncovers Distinct Archetypes of Human Aging (Li et al., October 14, 2025, arXiv, http://arxiv.org/abs/2510.12384v1 ) - We critically evaluate claims of distinct aging subtypes from multi-omics data, addressing concerns about false discovery rates and the fundamental challenge of distinguishing signal from noise in high-dimensional biological data. 3) A Population-scale Single-cell Spatial Transcriptomic Atlas of the Human Cortex (Han et al., Lingang Laboratory Shanghai, October 14, 2025, bioRxiv, https://www.biorxiv.org/content/10.1101/2025.10.13.681959v1 ) - We discuss this comprehensive brain atlas showing age-related neuronal vulnerability and glial activation, while noting its limitations as an observational study that cannot distinguish cause from consequence. 4) Chaperone-mediated autophagy regulates neuronal activity by sex-specific remodelling of the synaptic proteome (Khawaja et al., Albert Einstein College of Medicine, October 15, 2025, Nature Cell Biology, https://pubmed.ncbi.nlm.nih.gov/41087566/ ) - We explore how CMA activation restores synaptic function in aging models, highlighting the sex-specific effects and therapeutic potential while discussing translation challenges. 5) Accelerated Regeneration of Senescent Bone Injury through Age- and Sex-Independent Macrophage Polarization (Fukuda et al., Tokushima University, October 15, 2025, ACS Applied Materials and Interfaces, https://pubmed.ncbi.nlm.nih.gov/41091908/ ) - We examine phosphatidylserine liposomes for bone repair in aging, noting the age/sex-independent macrophage effects while questioning the broader applicability beyond orthopedic applications. We provide critical analysis of statistical limitations, experimental needs, and the reality that this represents a typical week where 95 percent of research is incremental rather than transformative for longevity biotech. This podcast is AI generated and may contain errors.

In this episode of Longevity Papers, we critically analyze the week of September 15-19, 2025 papers from longevitypapers.com for biotech researchers. We examine five papers: 1) The DREAM Complex Links Somatic Mutation, Lifespan, and Disease (Koch et al., UC San Diego, September 18, 2025, bioRxiv, https://www.biorxiv.org/content/10.1101/2025.09.15.676396v1 ) - We discuss how DREAM complex repression affects DNA repair and lifespan across 92 mammalian species, but question whether the modest 4.2% mutation reduction will translate to meaningful longevity gains. 2) Nucleosome Stability Safeguards Cell Identity, Stress Resilience and Healthy Aging (Tanaka et al., Sanford Burnham Prebys, September 18, 2025, bioRxiv, https://www.biorxiv.org/content/10.1101/2025.09.17.676776v1 ) - We explore cross-species evidence that nucleosome stability preserves cellular function, while noting the gap between artificial histone mutants and actionable interventions. 3) Estimating Universal Mammalian Lifespan via Age-Associated Epigenetic Entropy (Alba-Linares et al., CINN-CSIC, September 17, 2025, bioRxiv, https://www.biorxiv.org/content/10.1101/2024.09.06.611669v2 ) - We examine claims of a universal 220-year maximum mammalian lifespan based on epigenetic entropy patterns and discuss why correlation may not equal causation. 4) Metabolomic Signatures of Extreme Old Age from the New England Centenarian Study (Monti et al., Boston University, September 16, 2025, bioRxiv, https://www.biorxiv.org/content/10.1101/2025.09.10.675341v1 ) - We analyze bile acid elevation in centenarians while addressing survivor bias limitations in extreme longevity studies. 5) Guided Multi-Agent AI Invents Transcriptomic Aging Clocks (Agarwal et al., MIT, September 12, 2025, bioRxiv, https://www.biorxiv.org/content/10.1101/2025.09.08.674588v1 ) - We review this computational advance in aging clock accuracy while emphasizing that better measurement tools dont automatically translate to longevity breakthroughs. Throughout, we maintain skeptical analysis of whether these incremental findings will lead to the 10-year-plus lifespan extensions that longevity biotech truly needs. This podcast is AI generated and may contain errors.

This week on Longevity Papers, we didn't find so many interesting papers so we go back to a classic research by Cynthia Kenyon, but also analyze recent research from longevitypapers.com 1) The first long-lived mutants: discovery of the insulin/IGF-1 pathway for ageing. (Kenyon, Cynthia 12 January 2011 , Phil. Trans. R. Soc. B3669–16 https://doi.org/10.1098/rstb.2010.0276 ) 2) The aging factor EPS8 induces disease-related protein aggregation through RAC signaling hyperactivation (Koyuncu et al., University Hospital Cologne, Sept 4, 2025, https://pubmed.ncbi.nlm.nih.gov/40903652/ ) - Identifies EPS8 as a convergent aging factor promoting protein aggregation across multiple neurodegenerative diseases, with USP4 as a potential therapeutic target. 3) Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging (Zhang et al., University of Illinois Chicago, Sept 8, 2025, https://pubmed.ncbi.nlm.nih.gov/40920871/ ) - Demonstrates actual rejuvenation of aged hematopoietic stem cells through PF4 signaling, though systemic safety and lifespan effects remain to be proven. We discuss why most papers this week represent incremental progress rather than paradigm shifts, the challenges of translating promising mouse studies to humans, and what experiments are needed to validate these findings for meaningful life extension. This podcast is AI generated and may contain errors.

In this episode of Longevity Papers, we critically analyze recent research with appropriate skepticism for biotech researchers and longevity enthusiasts. First we discuss the ARDD conference that took last week in Copenhagen, including a replacement panel, and a related paper from Nature Aging back in May 2025: Replacement as an aging intervention (Sierra Lore et al., The Buck Institute, https://www.nature.com/articles/s43587-025-00858-6 ). Featured from longevitypapers.com: 1) Reprogramming Factors Activate a Non-Canonical Oxidative Resilience Pathway That Can Rejuvenate RPEs and Restore Vision (Lu et al., Whitehead Institute, September 01, 2025, bioRxiv, https://www.biorxiv.org/content/10.1101/2025.08.30.673239v1 ) - We examine claims that Yamanaka factors restore vision through GSTA4-mediated pathways, discussing why vision restoration studies require extreme caution and what validation experiments are needed. 2) Multi-modal atlas of lifestyle interventions reveals malleability of ageing-linked molecular features (Herzog et al., University of Innsbruck, September 01, 2025, bioRxiv, https://www.biorxiv.org/content/10.1101/2025.08.30.673115v1 ) - We analyze this comprehensive multi-omics study claiming intermittent fasting shows age-opposing molecular changes, explaining why 6-month biomarker studies rarely translate to meaningful longevity gains. 3) Avoidance Of Rejuvenation: A Stress Test For Evolutionary Theories Of Aging (Aisin et al., City University of Hong Kong, August 28, 2025, bioRxiv, https://www.biorxiv.org/content/10.1101/2025.08.24.671987v1 ) - We discuss this theoretical framework questioning why rejuvenation is rare in nature and whether this constrains intervention possibilities. As typical for most weeks, these papers represent incremental advances rather than paradigm shifts, with significant methodological limitations that require careful interpretation before any clinical applications. This podcast is AI generated and may contain errors.

In this episode of Longevity Papers, we critically analyze three moderately interesting research papers from longevitypapers.com: 1) Exoproteome of calorie-restricted humans identifies complement deactivation as an immunometabolic checkpoint reducing inflammaging (Mishra et al., Yale School of Medicine, August 06, 2025, bioRxiv, https://www.biorxiv.org/content/10.1101/2025.08.04.668533v1 ) - We examine how 14% caloric restriction for 2 years reduces complement protein C3a, potentially representing a key inflammaging checkpoint, though this builds on decades of CR research. 2) TSP50 in Neural Stem Cells Regulates Aging-Related Cognitive Decline and Neuroinflammation by Altering the Gut Microbiota (Li et al., Northeast Normal University, August 05, 2025, Aging Cell, https://pubmed.ncbi.nlm.nih.gov/40762371/ ) - We explore how neural stem cell TSP50 affects gut microbiota and cognitive aging, representing an interesting twist on gut-brain axis research despite the hype around microbiome studies. 3) Glial reactivity and cognitive decline follow chronic heterochromatin loss in neurons (Newman et al., Charité Berlin, August 09, 2025, PubMed, https://pubmed.ncbi.nlm.nih.gov/40781223/ ) - We discuss how heterochromatin loss leads to endogenous retrovirus activation and neuroinflammation, building on fundamental aging mechanisms but requiring human validation. Most papers this week represent incremental advances rather than breakthrough discoveries, highlighting the typical 95% probability that weekly research will not dramatically change longevity interventions.

In this episode of Longevity Papers, we critically analyze this weeks research with appropriate skepticism for biotech researchers and longevity enthusiasts. This week represents a typical collection where 95% of papers are incremental advances rather than paradigm-shifting discoveries. We examine three potentially interesting but limited studies: 1) Chronic activation of a key exercise signal transducer, CaMKII, drives skeletal muscle aging and sarcopenia (Bene et al., Johns Hopkins, August 02, 2025, https://www.biorxiv.org/content/10.1101/2025.07.30.667744v1 ) exploring antagonistic pleiotropy where beneficial exercise signals become harmful when chronically activated in aging muscle. While mechanistically interesting, this lacks lifespan data and systemic effects. 2) Targeting CyclinD1-CDK6 to Mitigate Senescence-Driven Inflammation and Age-Associated Functional Decline (Rajesh et al., Sanford Burnham Prebys, August 02, 2025, https://www.biorxiv.org/content/10.1101/2025.08.01.668243v1 ) identifying palbociclib as a potential senolytic. Promising because its FDA-approved, but major safety concerns for chronic use and no lifespan data. 3) Cyrene: A Novel Geroprotective Compound (AlOkda et al., McGill, August 01, 2025, https://www.biorxiv.org/content/10.1101/2025.08.01.668202v1 ) showing cross-species longevity effects with an industrial solvent. Highly skeptical this will translate - unclear mechanism and critical developmental window suggests its not addressing aging per se. Papers sourced from longevitypapers.com

In this episode of Longevity Papers, we analyze groundbreaking research from July 21-27, 2025: 1. LLM Predicts Organ Aging (Li et al., Nature Medicine): A large language model outperforms epigenetic clocks in mortality prediction using health reports. Discussing clinical potential and black-box limitations. (https://pubmed.ncbi.nlm.nih.gov/40702324 ) 2. DNA Methylation Atlas (Jacques et al., bioRxiv): Cross-tissue analysis identifies PCDHGA1 and NAD+ pathways as universal aging drivers. Debate on epigenetic entropy vs. resilience. (https://www.biorxiv.org/content/10.1101/2025.07.21.665830v1 ) 3. New Senolytic Target (Okamura et al., bioRxiv): GLS1 inhibitor BPTES eliminates senescent cells via glutamine metabolism. Exploring selectivity and translation hurdles. (https://www.biorxiv.org/content/10.1101/2025.07.22.666220v1 ) 4. Superager Brain Networks (Zhao et al., bioRxiv): fMRI-based connectome predicts resistance to Alzheimer’s. Can we enhance resilience neurostimulation? (https://www.biorxiv.org/content/10.1101/2025.07.20.665707v1 ) Full list at longevitypapers.com.

In this episode of Longevity Papers, we analyze groundbreaking research for biotech longevity scientists: JULY 2025 BREAKTHROUGHS: 1. Beyond the Pseudogene: p17/PERMIT as Mitochondrial Trafficking Protein (Albayram et al., Medical University of South Carolina, July 17) • Reclassification of "junk DNA" reveals mitochondrial chaperone critical for mitophagy\n • Loss accelerates sarcopenia and neurodegeneration • URL: https://pubmed.ncbi.nlm.nih.gov/40671432/ 2. RICTOR Regulates Longevity via Methionine-Mitophagy Axis (Motwani et al., National Institute of Immunology, July 10) • Vitamin B12-driven succinate accumulation activates mitophagy • Extends C. elegans lifespan through conserved nutrient-sensing pathway • URL: https://www.biorxiv.org/content/10.1101/2025.07.11.664440v1 3. Semaglutide Slows Epigenetic Aging in Humans (Corley et al., Weill Cornell, July 11) • GLP-1 agonist reduced GrimAge by 1.4-4.9 years in clinical trial • First evidence of epigenetic age reversal in HIV population\n • URL: https://www.medrxiv.org/content/10.1101/2025.07.09.25331038v1 4. ATF3 Deficiency in Vascular Aging (Nie et al., Huazhong University, July 11) • Terazosin stabilizes ATF3-ATG7 autophagy loop • Delays vascular smooth muscle cell senescence in aged mice • URL: https://pubmed.ncbi.nlm.nih.gov/40641410/ 5. Multi-Organ MRI Clocks Predict Mortality (MULTI Consortium, Columbia, July 12) • Brain/immune aging signatures emerge as top mortality predictors • 7-organ MRI analysis prioritizes 9 druggable targets • URL: https://www.medrxiv.org/content/10.1101/2025.07.10.25331263v1 6. Primate Rejuvenation via Engineered Stem Cells (Siddique et al., KAUST, June 27) • FOXO3-enhanced stem cells reversed multi-organ aging in monkeys • Reduced epigenetic age across brain/immune/reproductive systems • URL: https://pubmed.ncbi.nlm.nih.gov/40571786/ 7. Biomarker-Driven Geroprotector Discovery (Shindyapina et al., Harvard, June 30) • Platform identified selumetinib + vorinostat as lifespan-extenders • MEK/HDAC inhibitors extended healthspan in male mice • URL: https://www.biorxiv.org/content/10.1101/2025.06.26.661776v1 8. Engineered Telomerase RNA Therapy (Nagpal + Agarwal, Boston Children's, June 28) • Synthetic TERC extended telomeres in patient-derived stem cells • Solved delivery challenges for telomerase therapy • URL: https://pubmed.ncbi.nlm.nih.gov/40579489/ 9. ADIOL: Dietary Restriction's Neuroprotective Metabolite (Guijarro-Hernandez et al., UCSF, June 29) • Key mediator of calorie restriction benefits • Rescues APOE4-induced cellular stress • URL: https://www.biorxiv.org/content/10.1101/2025.06.25.661551v1 10. Mitochondrial Stress Response Modulator FIP1L1 (Li et al., EPFL, June 26) • Genetic mapping reveals conserved UPRmt regulator • Links mitochondrial proteostasis to longevity pathways • URL: https://www.biorxiv.org/content/10.1101/2025.06.26.661693v1 For full papers and daily longevity updates: https://longevitypapers.com Keywords: longevity research, aging biomarkers, epigenetic clocks, mitophagy, stem cell therapy, telomeres, geroprotectors, dietary restriction, mitochondrial health, neurodegeneration

In this episode of Longevity Papers, we critically analyze five cutting-edge research papers for biotech researchers and longevity enthusiasts, sourced from longevitypapers.com: 1) An Antagonistically Pleiotropic Gene Regulates Vertebrate Growth, Maturity and Aging (Moses et al., biorxiv, June 26, 2025, https://www.biorxiv.org/content/10.1101/2023.05.01.538839v3) - We explore powerful new evidence for the trade-off theory of aging, where a single gene in killifish drives early maturation at the cost of late-life cancer. 2) Comparative analysis of mouse strains for in vivo induction of reprogramming factors (Picó et al., Cell reports, June 25, 2025, https://pubmed.ncbi.nlm.nih.gov/40560729/) - We discuss the development of crucial new mouse models that aim to make systemic rejuvenation via Yamanaka factors safer, a critical step toward clinical translation. 3) Misalignment of age clocks (Mei et al., GeroScience, June 25, 2025, https://pubmed.ncbi.nlm.nih.gov/40560445/) - We delve into a critical paper from the Conboy lab that challenges the validity of our most-used biomarkers, the epigenetic clocks, and what it means for the field. 4) Epigenetic age prediction using N6-methyladenine in the bumblebee Bombus terrestris (Renard et al., biorxiv, June 26, 2025, https://www.biorxiv.org/content/10.1101/2025.06.20.660749v1) - We look at a completely novel type of epigenetic clock based on N6-methyladenine, a different DNA modification, that could open a new frontier in biomarker discovery. 5) Rejuvenation alleviates prolonged postsurgical pain in aging mice by mitigating inflammaging (Abdelkader et al., Pain, June 23, 2025, https://pubmed.ncbi.nlm.nih.gov/40546103/) - We examine how young blood factors can reverse age-related increases in post-surgical pain, reinforcing the role of systemic inflammaging in functional decline.

This week on Longevity Papers, we dissect five groundbreaking papers from the week of June 16th, 2025, sourced from LongevityPapers.com. We prioritize surprising findings from credible labs that challenge existing models in aging research. 1. The Mediator complex subunit Med19 extends healthy lifespan in Drosophila by preventing cellular and organismal frailty (Payet et al., RESTORE Research Center, June 18, 2025, BioRxiv: https://www.biorxiv.org/content/10.1101/2025.06.18.659864v1) - We start with the most significant paper of the week: a jaw-dropping claim of a nearly 90% median lifespan extension in fruit flies from upregulating a single gene, Med19. This effect size rivals the most potent interventions known. Well discuss how this master regulator of transcription could be a powerful control knob for aging, its potential for rejuvenation, and the healthy dose of skepticism required for a non-peer-reviewed paper with such a large effect. We compare this to other major lifespan-extending mutations in Drosophila, like those in the Indy gene, and discuss the importance of absolute vs. percentage increase given the variability in control lifespans. 2. An insulin-sensitive Drosophila insulin-like receptor mutant remodels methionine metabolism to extend lifespan. (Tatar et al., Brown University, June 16, 2025, PLoS Genetics: https://pubmed.ncbi.nlm.nih.gov/40523036/) - This elegant study tackles a core problem in longevity research: extending lifespan via the insulin/IGF-1 signaling (IIS) pathway often comes with nasty side effects like insulin resistance. The authors identified a specific mutation that uncouples these effects, providing longevity while maintaining health. Well break down how it achieves this by mimicking methionine restriction (MetR), beautifully linking two of the most robust longevity pathways. This work offers a more refined roadmap for developing gerotherapeutics that avoid the pitfalls of blunt pathway inhibition. 3. Lysergic Acid Diethylamide extends lifespan in Caenorhabditis elegans (Carrilho et al., DOr Institute for Research and Education, June 16, 2025, BioRxiv: https://www.biorxiv.org/content/10.1101/2025.06.16.659936v1) - In perhaps the most unexpected finding, researchers show that the classic psychedelic LSD extends lifespan in C. elegans. The key insight is that it appears to act as a caloric restriction (CR) mimetic, activating the key transcription factor PHA-4/FOXA without reducing food intake. This opens a completely new chemical space for geroprotector discovery. We discuss the challenge of human translation and what this implies for other, non-psychedelic serotonergic compounds. We contextualize this by comparing it to known CR mimetics like metformin and rapamycin. 4. Reversible proliferative arrest induced by rapid depletion of RNase MRP. (Liu et al., University of California, Riverside, June 19, 2025, Cell Proliferation: https://pubmed.ncbi.nlm.nih.gov/40533478/) - Achieving suspended animation is a holy grail of medicine. This paper presents a novel and surprisingly simple method to induce a long-term, yet fully reversible, state of quiescence in human cells by targeting ribosome biogenesis. Well discuss how this reinforces the rate of living theory and connects to longevity interventions like rapamycin. This provides a powerful new tool for research and a specific target for manipulating cellular states, with potential applications from organ preservation to extending healthspan. 5. A Nucleic Acid Prodrug That Activates Mitochondrial Respiration, Promotes Stress Resilience, and Prolongs Lifespan. (Anada et al., Kyushu University, June 13, 2025, Journal of the American Chemical Society: https://pubmed.ncbi.nlm.nih.gov/40512174/) - From the high-impact journal JACS, this paper describes a novel small molecule designed to directly combat mitochondrial dysfunction, a hallmark of aging. By increasing the pool of adenine nucleotides (ATP), the prodrug activates AMPK and markedly extends lifespan in C. elegans. Well explore the promise of this direct approach to boosting cellular energy and the critical need to consider long-term safety, as broadly boosting energy could have unintended consequences.

In this episode of Longevity Papers, we critically analyze a groundbreaking new paper for biotech researchers and longevity enthusiasts: A single factor for safer cellular rejuvenation by Camillo et al. from Shift Bioscience, posted to bioRxiv on June 6, 2025 (https://doi.org/10.1101/2025.06.05.657370). The paper introduces a single, anonymous gene, SB000, discovered through a novel rejuvenation-first screening platform. The authors claim SB000 rivals the rejuvenation potency of the famous Yamanaka factors (OSKM) without inducing the dangerous pluripotency that has hindered their therapeutic use. We delve into the multi-omic evidence, including the dramatic reversal of epigenetic clocks in both fibroblasts (Figure 2) and keratinocytes (Figure 4) - by as much as 13.6 years in skin cells. We also examine the crucial safety data from Figure 3, which shows SB000 preserves cellular identity and function, like collagen secretion, and, unlike OSK, fails to form pluripotent colonies in long-term culture. While the findings are exciting, we maintain a healthy skepticism, discussing the major limitations: this is an un-reviewed preprint, the identity of SB000 is a trade secret, the discovery relies on a proprietary black box clock, and all experiments are conducted in vitro, a far cry from a living organism. Finally, we propose the essential follow-up studies needed to validate these claims, from dissecting the genes mechanism of action to the critical in vivo proof-of-concept experiments in aged mice to test for true healthspan improvements and, most importantly, long-term safety.

In this episode of Longevity Papers, we critically analyze five cutting-edge research papers for biotech researchers and longevity enthusiasts: 1) The geroprotectors trametinib and rapamycin combine additively to extend mouse healthspan and lifespan (Gkioni et al., Max Planck Institute for Biology of Ageing, Published online: May 28, 2025, https://pubmed.ncbi.nlm.nih.gov/40437307/) - We delve into how combining trametinib (a Ras-MEK-ERK inhibitor) and rapamycin (an mTORC1 inhibitor) leads to an additive lifespan extension of up to 34.9% in female mice and 27.4% in male mice. We examine the significant healthspan improvements, including reduced tumor burden and systemic inflammation, and discuss the unique transcriptional changes induced by the combination therapy. We also critically assess the persistence of rapamycin-associated side effects like hyperglycemia and liver lipidosis. 2) A non-genotoxic stem cell therapy boosts lymphopoiesis and averts age-related blood diseases in mice (Konturek-Ciesla et al., Lund University, Published online: June 02, 2025, https://pubmed.ncbi.nlm.nih.gov/40456713/) - We explore a novel non-genotoxic conditioning regimen (CD45-SAP immunotoxin with G-CSF/AMD3100 mobilization) that allows for safe and effective transplantation of young hematopoietic stem cells (HSCs) into aged mice. We discuss the therapys success in improving hematopoietic output, restoring youthful naive T-cell populations, and preventing disease progression, including acute leukemia, in a mouse model of Myelodysplastic Syndrome (MDS). The major translational hurdle of sourcing young HSCs for human application is also considered. 3) Cell-type-specific patterns and consequences of somatic mutation in development and aging brain (Kriz, A. J., et al., Boston Children H_ospital, biorxiv, June 01, 2025, https://www.biorxiv.org/content/10.1101/2025.05.30.656844v1) - We analyze the introduction of Duplex-Multiome, a new technique allowing simultaneous identification of somatic single-nucleotide variants (sSNVs) along with single-nucleus chromatin accessibility (snATAC-seq) and gene expression (snRNA-seq). We discuss findings that different brain cell types exhibit unique age-related somatic mutation patterns and how these mutations can correlate with changes in gene expression, potentially linking somatic mutagenesis directly to functional changes in the aging brain. 4) Pasta, an age-shift transcriptomic clock, maps the chemical and genetic determinants of aging and rejuvenation (Salignon, J., et al., Karolinska Institute, biorxiv, June 04, 2025, https://www.biorxiv.org/content/10.1101/2025.06.04.657785v1) - We examine Pasta, a novel transcriptomic aging clock designed to be robustly applicable across various data types. We look into its use in identifying known and novel age-modulatory compounds and genetic perturbations from large datasets, with piperlongumine validated as a rejuvenating agent. The discussion covers its potential as a discovery tool for new geroprotectors by linking aging signatures to p53 and DNA damage response pathways. 5) Nephronectin (NPNT) is a Crucial Determinant of Idiopathic Pulmonary Fibrosis: Modulating Cellular Senescence via the ITGA3/YAP1 Signaling Axis (Guo, J., et al., Harbin Medical University, Advanced Science, May 30, 2025, https://pubmed.ncbi.nlm.nih.gov/40444575/) - We review findings identifying Nephronectin (NPNT) as a molecule whose expression is reduced in Idiopathic Pulmonary Fibrosis (IPF) and which plays a role in modulating cellular senescence via the ITGA3/YAP1 signaling pathway. We discuss how NPNT deficiency exacerbates fibrosis and senescence, while its overexpression or pharmacological elevation using Escin can be protective in mouse models of IPF, offering potential new therapeutic avenues for this age-related disease. Throughout the episode, we critically evaluate the methodologies, interpret key data from the full papers where available, maintain a skeptical stance on preliminary findings, and propose essential follow-up experiments to further validate and expand upon these important contributions to longevity research.

In this episode of Longevity Papers, we critically analyze five groundbreaking research papers for biotech researchers and longevity enthusiasts: 1) Lysosomes Signal through Epigenome to Regulate Longevity across Generations (Zhang et al., HHMI Janelia Research Campus, May 24, 2025, https://www.biorxiv.org/content/10.1101/2025.05.21.652954v1) - We explore how lysosomal metabolic pathways regulate transgenerational longevity in C. elegans via H3.3 histone transport and H3K79 methylation. The germline-specific epigenetic inheritance mechanism challenges conventional views of aging as irreversible. We discuss the controversial implications for mammalian reprogramming. 2) Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Therapeutic Plasma Exchange (Fuentealba et al., Buck Institute for Research on Aging, May 27, 2025, https://pubmed.ncbi.nlm.nih.gov/40424097/) - We examine how therapeutic plasma exchange reversed epigenetic aging in 42 older adults across 15 clocks. The monthly protocol showed strongest effects but raises questions about IVIG confounding and whether this represents true multi-omic reset versus transient biomarker modulation. 3) Improving Cellular Senescence Detection with Weak Gene Markers in Single-Cell RNA-seq via Iterative Imputation (Xu et al., Southeast University, May 29, 2025, https://www.biorxiv.org/content/10.1101/2025.05.25.656048v1) - We analyze the ICE computational framework that boosts senescent cell detection accuracy from 56% to 98% in pancreatic tissue. The method overcomes limitations of weak markers like p16 and enables precise mapping in Alzheimers microglia, potentially resolving controversies in senolytic efficacy studies. 4) Multiplexed Targeted Spatial Mass Spectrometry Imaging Assays to Monitor Lipids and NAD+ Metabolites in CD38 Knockout Mice (Schurman et al., Buck Institute for Research on Aging, May 26, 2025, https://www.biorxiv.org/content/10.1101/2025.05.25.655991v1) - We investigate the iprm-PASEF imaging technique that revealed increased NAD+ and altered lipid distribution in CD38-/- livers at subcellular resolution. The spatial metabolomics approach provides unprecedented insight but raises questions about immune tradeoffs of CD38 inhibition. 5) Telomeric Antisense Oligonucleotides Reduce Premature Aging Phenotypes in Telomerase Mutant Zebrafish (Allavena et al., Institute for Research on Cancer and Aging of Nice, May 27, 2025, https://www.biorxiv.org/content/10.1101/2025.05.23.655694v1) - We review how single-dose tASOs rescued developmental defects and enhanced fertility in telomerase-deficient zebrafish by inhibiting tncRNA-mediated DNA damage response. The transgenerational effects suggest epigenetic reprogramming but highlight zebrafish-mammalian translation challenges. Throughout the episode, we delve into experimental methods, interpret figures beyond the abstracts, maintain healthy skepticism toward preliminary findings, and propose crucial follow-up studies to validate each papers conclusions. Special focus is given to the paradigm-shifting implications of lysosomal epigenetics and clinical translation of plasma exchange rejuvenation.

In this episode of Longevity Papers, we critically analyze five cutting-edge research papers for biotech researchers and longevity enthusiasts: 1) "Muscle peripheral circadian clock drives nocturnal protein degradation via raised Ror/Rev-erb balance and prevents premature sarcopenia" (Kelu, Hughes, King's College London, May 05, 2025, https://pubmed.ncbi.nlm.nih.gov/40324...) - We explore how the muscle's intrinsic clock regulates protein degradation pathways (UPS and autophagy) at night, with clock disruption causing initial muscle growth but accelerating sarcopenia. The zebrafish model reveals the Ror/Rev-erb balance as a potential therapeutic target. 2) "Fucoidans are senotherapeutics that enhance SIRT6-dependent DNA repair" (Zhang et al., University of Minnesota, April 28, 2025, https://www.biorxiv.org/content/10.11...) - We examine how these brown algae compounds activate SIRT6 to reduce cellular senescence and enhance DNA repair in accelerated aging mice. We discuss the study's limitations including the lack of lifespan data in normal aging models and the need for standardized fucoidan formulations. 3) "Genetic correlation-guided mega-analysis of DO mice provides mechanistic insight for age-related pathologies" (Mullis et al., Calico Life Sciences, May 17, 2025, https://www.biorxiv.org/content/10.11...) - We analyze this comprehensive study of 7,233 phenotypes in Diversity Outbred mice, which challenges existing paradigms by showing weak correlation between lifespan and frailty genetics while highlighting immune cell composition as a key factor. 4) "The broccoli derivative sulforaphane extends lifespan by slowing the transcriptional aging clock" (Sedore et al., University of Oregon, May 16, 2025, https://www.biorxiv.org/content/10.11...) - We investigate how this natural compound extends C. elegans lifespan by 50% through hormetic detoxification pathways, while questioning the translational relevance and proposing mammalian validation studies. 5) "AI-Driven Identification of Exceptionally Efficacious Polypharmacological Compounds That Extend Lifespan" (Avchaciov et al., Gero PTE, April 22, 2025, https://pubmed.ncbi.nlm.nih.gov/40260...) - We review how AI-designed multi-target compounds achieved remarkable lifespan extension in C. elegans, representing a paradigm shift in geroprotector development. Throughout the episode, we delve into experimental methods, interpret figures beyond the abstracts, maintain healthy skepticism toward preliminary findings, and propose crucial follow-up studies to validate or challenge each paper's conclusions.

Paper Title: Boosting Cellular Longevity Through Intracellular ATP Modulation Authors: Naci Oz, Hetian Su, Praveen Patnaik, Derek C. Prosser, Vyacheslav M. Labunskyy, Rohil Hameed, Vadim N. Gladyshev, Nan Hao, Alaattin Kaya Institution: University of Virginia, University of California San Diego, Boston University, Harvard Medical School Date: April 16, 2025 Link: https://www.biorxiv.org/content/10.1101/2025.04.14.648769v1 Key Findings: Engineered yeast with a parasitic ATP transporter (NTT1) showed ATP depletion shortens lifespan, while supplementation extends it. Dual mechanisms: mitochondrial suppression (catabolism) and extracellular ATP sensing (MAPK activation). 40% lifespan extension in NTT1 yeast (p=4.03E-18), but high-dose ATP caused toxicity in mitochondrial-competent cells (Fig 6B). Limitations: Yeast models lack human aging complexity (e.g., inflammation, systemic decline). Next Steps: Validate in mammals, identify ATP-sensing receptors, test combinatorial therapies (e.g., ATP + rapamycin). Paper Title: HDAC11 Deficiency Regulates Age-Related Muscle Decline and Sarcopenia Authors: Renato Odria, Aina Cardús, Clara Gomis-Coloma, Ulalume Hernández-Arciga, Ceda Stamenkovic, Shweta Yadav Institution: Institut d'Investigació en Ciències de Salut Germans Trias i Pujol, Spain Date: April 12, 2025 Link: https://pubmed.ncbi.nlm.nih.gov/40220154/ Key Findings: HDAC11-deficient aged mice resisted sarcopenia: 26% larger type IIb muscle fibers (p less than 0.0001), 55% fewer lipid droplets (Fig 6B), and ω-6/ω-3 ratio reversal (3.5 → 1.8). 50% increase in PAX7⁺ satellite cells post-injury, suggesting enhanced regeneration. Limitations: Small cohort (n=19 KO mice), survival bias (0% mortality vs. 27% in WT), no dietary controls. Next Steps: Muscle-specific KO models, lysine-myristoylation proteomics, in vivo electrophysiology. Comparative Insights: Both studies target metabolic pathways (ATP/HDAC11) but lack translational rigor. Yeast highlights energy flux; mice emphasize lipid/metabolic reprogramming. Critical gap: Human relevance unproven. Prioritize muscle-specific and dose-controlled studies.

Paper: Epigenetic editing at individual age-associated CpGs affects the genome-wide epigenetic aging landscape. Authors: Liesenfelder, S., Elsafi Mabrouk, M.H., Iliescu, J. *et al.*. The corresponding author is Wolfgang Wagner. Journal: Nature Aging Published: 24 March 2025. DOI: https://doi.org/10.1038/s43587-025-00841-1 (This DOI can be used to access the paper.) This week, we delve into a fascinating paper from Nature Aging that explores the impact of **epigenetic editing at individual age-associated CpG sites on the broader epigenetic aging landscape**. Researchers, including S. Liesenfelder and Wolfgang Wagner, utilized CRISPR-based editing tools (dCas9-DNMT3A, CRISPRoff) to target specific CpG sites and observed **genome-wide methylation changes, termed "bystander effects"**. These effects were found to be **reproducible and linked to 3D chromatin interactions**. Notably, **hypermethylation at age-associated sites showed greater stability compared to hypomethylated targets**. This paper raises some critical questions for the longevity biotech field: As one talking point suggests, **"If aging is an orchestra, this paper shows the musicians talk to each other—but we still don’t know who’s the conductor"**. How do these localized epigenetic edits propagate and influence the wider genome? Another point to consider: **"Editing one CpG is like poking a spiderweb: the whole structure vibrates, but does it matter for the spider?"**. Are these genome-wide changes functionally significant for the aging process? The study uses **epigenetic clocks**, which are highlighted as **"like a car’s dashboard warning lights. Fixing the light doesn’t fix the engine"**. Does altering these clocks through epigenetic editing truly impact the underlying mechanisms of aging, or are we just tweaking a biomarker? While the paper demonstrates these bystander effects, it's important to consider the magnitude of the changes, with opinions noting that the hyper-CpG changes in Fig 5ab may not be that impressive. The relevance of epigenetic clocks for interventions also needs scrutiny, as they are not yet fully validated for this purpose. There's potential for applying information theory and compression concepts to better understand the communication within this epigenetic network. We will discuss the potential implications of these "bystander effects" and consider the limitations of using epigenetic clocks as direct targets for anti-aging therapies, especially in the absence of more supporting research. We will also briefly touch on related research in epigenetic editing and its broader applications.

Inhibition of Ferroptosis Delays Aging and Extends Healthspan Across Multiple Species (March 31, 2025) Institution: Southwest Medical University, Luzhou, Sichuan, China Relevance: The study finds that ferroptosis—a form of iron-dependent cell death—is a key driver of cellular senescence. Inhibiting ferroptosis extends lifespan and improves healthspan in both C. elegans and mice. The cross-species effects are compelling, yet long-term safety and broader applicability remain to be explored. • Doxifluridine Promotes Host Longevity through Bacterial Metabolism (March 31, 2025) Institution: West China Hospital, Sichuan University, Chengdu, China Relevance: Using a dual-fluorescent splicing reporter in C. elegans, this research identifies doxifluridine as a lead compound that rescues age-related alternative splicing defects—its efficacy being dependent on bacterial metabolism. This host–microbe interplay opens a novel therapeutic avenue but needs further mechanistic validation in higher organisms. • Neuronal Antenna Senses Signals from the Bone to Sustain Cognition by Boosting Autophagy (April 2025) Institution: Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, Paris, France Relevance: This study shows that bone-derived BGLAP/osteocalcin acts via an “extracellular antenna” in hippocampal neurons to enhance autophagy and improve cognitive resilience in aging. While promising in linking systemic factors to brain health, its overall impact on lifespan extension is still uncertain. • Senescent Endothelial Cells in Cerebral Microcirculation Are Key Drivers of Age-Related Blood-Brain Barrier Disruption, Microvascular Rarefaction, and Neurovascular Coupling Impairment in Mice (April 2025) Institution: University of Oklahoma Health Sciences Center Relevance: The paper demonstrates that senescent endothelial cells contribute to neurovascular decline, disrupting the blood-brain barrier and impairing cognitive function. It suggests that targeting these cells could restore neurovascular health in aging, although caution is warranted given the variable results of senolytic interventions. • Single Cell-Resolved Cellular, Transcriptional, and Epigenetic Changes in Mouse T Cell Populations Linked to Age-Associated Immune Decline (March 31, 2025) Institution: Regeneron Pharmaceuticals, Tarrytown, NY, USA Relevance: This comprehensive single-cell analysis maps how T cell populations change with age, pinpointing alterations that may underlie immune decline. These insights could pave the way for targeted interventions to rejuvenate immune function in the elderly, though translation to human systems will be a major challenge. For a deep dive in our discussion, we'll focus on the doxifluridine and ferroptosis inhibition studies—both of which offer novel, cross-species strategies that might translate into significant longevity gains if further validated. Note: While each paper provides valuable mechanistic insights, the overall picture suggests these findings are incremental and require additional corroboration to be considered game-changing in the field of longevity research.

Bisphosphonates Trigger Anti-Ageing Effects Across Multiple Cell Types and Protect Against Senescence Lu, J., Rao, S. R., Knowles, H. ... · cell biology · Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK · biorxiv Longevity Relevance Analysis (5) Bisphosphonates may trigger anti-aging effects by protecting against cellular senescence and modifying the plasma proteome. The paper addresses mechanisms that could potentially influence the root causes of aging, rather than merely treating age-related diseases. Wednesday, March 26, 2025 [11]Targeted intervention of senescence induced by a 5' half fragment of tRNASec(NCA) with antisense oligonucleotide extends healthspan and lifespan in mice Cao, K.-Y., Bai, L.-B., Zhang, D. ... · genetics · State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology · biorxiv Longevity Relevance Analysis (5) The paper claims that targeting the 5'-tRNASec(NCA) half with antisense oligonucleotides can ameliorate aging markers and extend healthspan and lifespan in mice. This research addresses a potential root cause of aging by identifying tRNA damage as a novel aging hallmark and proposing a therapeutic intervention, which is significant for the field of longevity research. Tuesday, March 25, 2025 [17]Epigenetic editing at individual age-associated CpGs affects the genome-wide epigenetic aging landscape. Sven Liesenfelder, Mohamed H Elsafi Mabrouk, Jessica Iliescu ... · Nature aging · Institute for Stem Cell Biology, RWTH Aachen University Medical School, Aachen, Germany. · pubmed Longevity Relevance Analysis (5) The paper claims that epigenetic editing at age-associated CpG sites can modulate the epigenetic aging network and interfere with epigenetic clocks. This research is relevant as it explores the mechanisms of aging at the epigenetic level, potentially addressing the root causes of aging rather than merely treating age-related diseases. Saturday, March 22, 2025 [45]Exosomes Released from Senescent Cells and Circulatory Exosomes Isolated from Human Plasma Reveal Aging-associated Proteomic and Lipid Signatures Patel, S. K., Bons, J., Rose, J. P. ... · cell biology · Buck Institute for Research on Aging · biorxiv Longevity Relevance Analysis (5) The paper identifies specific proteomic and lipidomic signatures in exosomes from senescent cells and human plasma that are associated with aging. This research is relevant as it explores the mechanisms of cellular senescence, which is a fundamental process in aging and age-related diseases, potentially leading to therapeutic targets for longevity interventions. Wednesday, March 26, 2025 [15]SIRT6 activator fucoidan extends healthspan and lifespan in aged wild-type mice Biashad, S. A., Hillpot, E., Morandini, F. ... · molecular biology · University of Rochester · biorxiv Longevity Relevance Analysis (4) Fucoidan supplementation activates SIRT6, leading to increased lifespan and reduced frailty in aged mice. The paper is relevant as it investigates a potential pharmacological approach to enhance longevity through the activation of a protein associated with lifespan extension and healthspan improvement. The podcast is auto-generated by NotebookLM and frankly, has occasional mistakes on the date of the paper and the authors, but mostly describes the overall idea of the research and papers well. I'm trying it out for a few weeks to see if it's worth continuing to generate the podcast.

1. Inhibition of PIKfyve kinase induces senescent cell death by suppressing lysosomal exocytosis and leads to improved outcomes in a mouse model of idiopathic pulmonary fibrosis https://www.biorxiv.org/content/10.11... Authors: Barkovskaya, A., Kim, K., Shankar, A. et al. Journal: Biorxiv Institution: Lifespan Research Institute Summary: This paper identifies PIKfyve kinase inhibition as a novel senolytic strategy that selectively kills senescent cells by blocking lysosomal exocytosis. The study demonstrates that the small molecule apilimod effectively removes senescent cells in vitro and in vivo, improving outcomes in a pulmonary fibrosis model. This research is highly relevant as it targets cellular senescence, a root cause of aging, and offers a potential therapeutic approach for age-related diseases. Potential Impact: This paper could significantly impact the field by providing a new senolytic drug candidate with translational potential for treating age-related diseases. 2. Bcl-xL overexpression in T cells preserves muscle mitochondrial structure and function and prevents frailty in old mice Paper: https://pubmed.ncbi.nlm.nih.gov/40106... Authors: Cristina Mas-Bargues, Aurora Román-Domínguez, Jorge Sanz-Ros et al. Journal: PubMed Institution: Freshage Research Group, University of Valencia, Spain Summary: This study shows that overexpression of the anti-apoptotic protein Bcl-xL in T cells enhances immune function, preserves mitochondrial integrity, and delays frailty in aging mice. The findings suggest that Bcl-xL plays a crucial role in healthy aging by improving cellular resilience and reducing inflammation. Potential Impact: This research highlights the importance of immune system modulation in aging and could lead to new therapies targeting mitochondrial health and immune function to extend healthspan. 3. A Xanthine Derivative With Novel Heat Shock Protein 90-Alpha Inhibitory and Senolytic Properties Paper: https://pubmed.ncbi.nlm.nih.gov/40098... Authors: Sandra Atlante, Luca Cis, Davide Pirolli et al. Journal: Aging Cell Institution: Laboratory of Epigenetics, Istituti Clinici Scientifici Maugeri IRCCS, Italy Summary: This paper introduces a novel xanthine derivative, K5, which exhibits significant senolytic activity and extends lifespan in model organisms. K5 targets HSP90α and selectively eliminates senescent cells, showing potential for combating age-related diseases and inflammaging. Potential Impact: K5 represents a promising new senolytic compound with multimodal action, potentially offering a safer and more effective intervention for age-related diseases and lifespan extension. 4. TMBIM-2 orchestrates systemic mitochondrial stress response via facilitating Ca2+ oscillations Paper:https://pubmed.ncbi.nlm.nih.gov/40100... Authors: Jiasheng Li, Jimeng Cui, Xinyu Li et al. Journal: PubMed Institution: State Key Laboratory of Molecular Developmental Biology, Chinese Academy of Sciences Summary: This study identifies TMBIM-2 as a key mediator of mitochondrial stress responses that influence aging and lifespan in C. elegans. TMBIM-2 regulates Ca2+ oscillations, which are critical for mitochondrial function and stress adaptation. Overexpression of TMBIM-2 counteracts age-related decline and extends lifespan. Potential Impact: This research provides insights into the molecular mechanisms linking mitochondrial stress to aging and suggests TMBIM-2 as a potential target for interventions to counteract age-related decline. 5. Epigenetic age acceleration and mortality risk prediction in US adults Paper: https://link.springer.com/article/10.... Authors: Angelico Mendy, Tesfaye B Mersha Journal: GeroScience Institution: University of Cincinnati College of Medicine Summary: This paper examines the predictive power of epigenetic age acceleration (EAA) for all-cause, cardiovascular, and cancer mortality. The study demonstrates that EAA, particularly using the GrimAge clock, is a robust predictor of mortality risk, independent of chronological age. Potential Impact: This research underscores the importance of epigenetic clocks in assessing biological aging and mortality risk, providing a tool for early intervention and personalized medicine in aging populations. The podcast is auto-generated by NotebookLM and frankly, has occasional mistakes on the date of the paper and the authors, but mostly describes the overall idea of the research and papers well. I'm trying it out for a few weeks to see if it's worth continuing to generate the podcast.

Longevity Papers 2025-03-13 The Longevity Papers podcast focuses on the latest research papers in longevity biotech. This podcast episode covers a few of the tens of papers in https://longevitypapers.com, which finds the latest interesting papers with longevity focus from preprint servers. The podcast is auto-generated by NotebookLM and frankly, has occasional mistakes on the date of the paper and the authors, but mostly describes the overall idea of the research and papers well. I'm trying it out for a few weeks to see if it's worth continuing to generate the podcast.

Longevity Papers 2025-03-06 The Longevity Papers podcast focuses on the latest research papers in longevity biotech. This podcast episode covers a few of the tens of papers in https://longevitypapers.com, which finds the latest interesting papers with longevity focus from preprint servers. The podcast is auto-generated by NotebookLM and frankly, has occasional mistakes on the date of the paper and the authors, but mostly describes the overall idea of the research and papers well. I'm trying it out for a few weeks to see if it's worth continuing to generate the podcast.

Longevity Papers 2025-02-27 The Longevity Papers podcast focuses on the latest research papers in longevity biotech. This podcast episode covers a few of the tens of papers in https://longevitypapers.com, which finds the latest interesting papers with longevity focus from preprint servers. The podcast is auto-generated by NotebookLM and frankly, has occasional mistakes on the date of the paper and the authors, but mostly describes the overall idea of the research and papers well. I'm trying it out for a few weeks to see if it's worth continuing to generate the podcast.

Longevity Papers 2025-02-20 The Longevity Papers podcast focuses on the latest research papers in longevity biotech. This podcast episode covers a few of the tens of papers in https://longevitypapers.com, which finds the latest interesting papers with longevity focus from preprint servers. The podcast is auto-generated by NotebookLM and frankly, has occasional mistakes on the date of the paper and the authors, but mostly describes the overall idea of the research and papers well. I'm trying it out for a few weeks to see if it's worth continuing to generate the podcast.

Longevity Papers 2025-02-13 The Longevity Papers podcast focuses on the latest research papers in longevity biotech. This podcast episode covers a few of the tens of papers in https://longevitypapers.com, which finds the latest interesting papers with longevity focus from preprint servers. The podcast is auto-generated by NotebookLM and frankly, has occasional mistakes on the date of the paper and the authors, but mostly describes the overall idea of the research and papers well. I'm trying it out for a few weeks to see if it's worth continuing to generate the podcast.

Longevity Papers 2025-02-05 The Longevity Papers podcast focuses on the latest research papers in longevity biotech. This podcast episode covers a few of the tens of papers in https://longevitypapers.com, which finds the latest interesting papers with longevity focus from preprint servers. The podcast is auto-generated by NotebookLM and frankly, has occasional mistakes on the date of the paper and the authors, but mostly describes the overall idea of the research and papers well. I'm trying it out for a few weeks to see if it's worth continuing to generate the podcast.

Longevity Papers 2025-01-30 The Longevity Papers podcast focuses on the latest research papers in longevity biotech. This podcast episode covers a few of the tens of papers in https://longevitypapers.com, which finds the latest interesting papers with longevity focus from preprint servers. The podcast is auto-generated by NotebookLM and frankly, has occasional mistakes on the date of the paper and the authors, but mostly describes the overall idea of the research and papers well. I'm trying it out for a few weeks to see if it's worth continuing to generate the podcast.

Longevity Papers 2025-01-23 The Longevity Papers podcast focuses on the latest research papers in longevity biotech. This podcast episode covers a few of the tens of papers in https://longevitypapers.com, which finds the latest interesting papers with longevity focus from preprint servers. The podcast is auto-generated by NotebookLM and frankly, has occasional mistakes on the date of the paper and the authors, but mostly describes the overall idea of the research and papers well. I'm trying it out for a few weeks to see if it's worth continuing to generate the podcast.

Longevity Papers 2025-01-16 The Longevity Papers podcast focuses on the latest research papers in longevity biotech. This podcast episode covers a few of the tens of papers in https://longevitypapers.com, which finds the latest interesting papers with longevity focus from preprint servers. The podcast is auto-generated by NotebookLM and frankly, has occasional mistakes on the date of the paper and the authors, but mostly describes the overall idea of the research and papers well. I'm trying it out for a few weeks to see if it's worth continuing to generate the podcast.

Longevity Papers 2025-01-09 The Longevity Papers podcast focuses on the latest research papers in longevity biotech. This podcast episode covers a few of the tens of papers in https://longevitypapers.com, which finds the latest interesting papers with longevity focus from preprint servers. The podcast is auto-generated by NotebookLM and frankly, has occasional mistakes on the date of the paper and the authors, but mostly describes the overall idea of the research and papers well. I'm trying it out for a few weeks to see if it's worth continuing to generate the podcast.

Longevity Papers 2025-01-02 The Longevity Papers podcast focuses on the latest research papers in longevity biotech. This podcast episode covers a few of the tens of papers in https://longevitypapers.com, which finds the latest interesting papers with longevity focus from preprint servers. The podcast is auto-generated by NotebookLM and frankly, has occasional mistakes on the date of the paper and the authors, but mostly describes the overall idea of the research and papers well. I'm trying it out for a few weeks to see if it's worth continuing to generate the podcast.

Longevity Papers 2024-12-27 The Longevity Papers podcast focuses on the latest research papers in longevity biotech. This podcast episode covers a few of the tens of papers in https://longevitypapers.com, which finds the latest interesting papers with longevity focus from preprint servers. The podcast is auto-generated by NotebookLM and frankly, has occasional mistakes on the date of the paper and the authors, but mostly describes the overall idea of the research and papers well. I'm trying it out for a few weeks to see if it's worth continuing to generate the podcast.